Avalon GloboCare Corp (NASDAQ:ALBT) announced that Laboratory Services MSO (LSM) is now offering an in-house laboratory-developed test to detect tuberculosis using a patient’s sputum sample.
Avalon owns a 40% interest in Laboratory Services (LSM).
Laboratory Services’ new PCR test allows for accurately and rapidly identifying Mycobacterium tuberculosis (Mtb) from samples.
Using sputum samples to detect Mtb provides easier collection and transport than blood samples in protein-based chemiluminescent immunoassays.
The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.
The skin test is a 120-year-old test that requires the patient to make repeat visits to the clinic, followed by a chest X-ray to confirm a positive test result.
The skin test takes several days to show a reaction. LSM’s PCR-based test can be performed in under 2 hours, and the patient needs only one visit to the clinic to provide a sputum sample with no needle stick required.
Most frequently, TB affects the lungs. However, it can also cause disease in any part of the body. TB kills about 1.4 million people each year worldwide.
Price Action: ALBT shares closed at $0.94 on Tuesday.
